

# ESCP CRAFT Study

Cryptoglandular Anal Fistula Treatment

The new international, prospective  
combined Audit & Cohort Study



UNIVERSITY OF  
BIRMINGHAM

# Study management group

**N. Tabaković**



**P. Tozer**



**D. Zimmerman**



**A. El-Hussuna**



**T. Pinkney**




**L. Magill**



**J. Keatley**



**M. Pettitt**




**M. Kimman**



**S. van Kuijk**



**E. Mitalas**



**S. Breukink**



# National coordinators

Felix Aigner, Austria

Gerd Silberhumer, Austria

Japser Stijns, Belgium

Martin Karamanliev, Bulgaria

Petr Vlček, Czech Republic

Kristin Steinhorsdottir, Denmark

Mostafa Shalaby, Egypt

Niki Christou, France

Ingo Alldinger, Germany

George Tzovaras, Greece

Ioannis Katsaros, Greece

Gabriella Capolupo, Italy

Francesco Pata, Italy

Gaetano Gallo, Italy

Elsa Valsdóttir, Iceland

Nicolas Avellaneda, Latin America

Paulius Žeromskas, Lithuania

Mihd Firdaus Mohd Hayati, Malaysia

Marjolein Leeuwenburgh, Netherlands

Nuno Rama, Portugal

Christian Blajut, Romania

Hector Guadalajara Labajo, Spain

Ahmed Mohamed Ibrahim Mohamed, Sudan

Sezai Leventoglu, Turkey

Ali Farsi, Saudi Arabia

Fabian Grass, Switzerland

Sergii Podpriatov, Ukraine


Sara Al-Bastaki, United Arab Emirates


Anjelli Wagnakumar, United States of America

Kapil Sahnun, United Kingdom

# Current Outreach

## 218 interested centers | 49 countries





# Cryptoglandular Anal Fistula

Meta-Analysis > Colorectal Dis. 2024 Jan;26(1):145-196. doi: 10.1111/codi.16741.

Epub 2023 Dec 5.

## European Society of Coloproctology: Guidelines for diagnosis and treatment of cryptoglandular anal fistula

Lillian Reza<sup>1</sup>, Kevin Gottgens<sup>2</sup>, Jos Kleijnen<sup>3</sup>, Stephanie Breukink<sup>4</sup>, Peter C Ambe<sup>5</sup>, Felix Aigner<sup>6</sup>, Erman Aytac<sup>7</sup>, Gabriele Bislenghi<sup>8</sup>, Andreas Nordholm-Carstensen<sup>9</sup>, Hossam Elfeki<sup>10</sup>, Gaetano Gallo<sup>11</sup>, Ugo Grossi<sup>12</sup>, Baris Gulcu<sup>13</sup>, Nusrat Iqbal<sup>1</sup>, Rosa Jimenez-Rodriguez<sup>14</sup>, Sezai Leventoglu<sup>15</sup>, Giorgio Lisi<sup>16</sup>, Francesco Litta<sup>17</sup>, Philip Lung<sup>1</sup>, Monica Millan<sup>18</sup>, Ersin Ozturk<sup>13</sup>, Charlene Sackitey<sup>1</sup>, Mostafa Shalaby<sup>19</sup>, Jasper Stijns<sup>20</sup>, Phil Tozer<sup>1</sup>, David Zimmerman<sup>21</sup>

Affiliations + expand

PMID: 38050857 DOI: 10.1111/codi.16741




# Objectives

## CRAFT Audit: Practice variation, Short-term outcomes, FU 3 months



## CRAFT Cohort: PROMs, Long-term outcomes, FU 12 months



# Anal Fistula Core Outcome Set

## Clinician reported outcomes

### Clinical fistula healing

- Defined as: absence of any discharge symptoms, absence of abscess, infection or inflammation, and no recurrence or persistence of the fistula
- Healing is achieved after a 6 month discharge symptom free period

### Recurrence

### Radiological healing: **NOT MANDATORY**

- Modality: MRI
- Defined as: the complete resolution of any visible fistula tract and inflammatory mass +/- formation of fibrosis within the tract

### Development of additional fistula

### Complications and reinterventions

- Complications: Clavien Dindo Classification
- Reinterventions only refer to surgical and radiological reinterventions



# Anal Fistula Core Outcome Set

## Patient reported outcomes

### Quality of life/ symptoms/ psychological impact

- Anal Fistula Quality of Life Questionnaire (AF-QoL)
- EQ-5D

### Incontinence

- St. Marks (Vaizey) Incontinence Score

### Financial impact on healthcare systems

- Work Productivity Activity Index (WPAI )
- EQ-5D

### Patient satisfaction

- Numerical Rating Score (NRS)

#### AF-QoL: The Anal Fistula Quality of Life Scale

The aim of this questionnaire is to understand the impact that your fistula is having on your daily life, and the adjustments you are having to make because of it.

The following questions ask about your fistula, the symptoms it gives you and how they have affected your life over the last 4-6 weeks. Please answer all the questions. If you are unsure about how to answer any question, just give the best answer you can.

Do not spend too much time thinking about your answer, as your first thoughts are likely to be the most accurate. If you do not wish to answer any of these questions, please leave it blank, or leave details of the reason(s) why it was not answered.

#### Part 1: Your symptoms:

On average, over the last 4-6 weeks:

##### 1) How often have you experienced pain or discomfort from your fistula?

- |                        |     |                          |
|------------------------|-----|--------------------------|
| a) Never               | 100 | <input type="checkbox"/> |
| b) Occasionally        | 75  | <input type="checkbox"/> |
| c) A few times a week  | 50  | <input type="checkbox"/> |
| d) Daily               | 25  | <input type="checkbox"/> |
| e) Several times a day | 0   | <input type="checkbox"/> |

##### 2) How severe has the pain from your fistula been?

- |                              |     |                          |
|------------------------------|-----|--------------------------|
| a) No pain at all            | 100 | <input type="checkbox"/> |
| b) Mild pain                 | 75  | <input type="checkbox"/> |
| c) Moderate pain             | 50  | <input type="checkbox"/> |
| d) Severe pain               | 25  | <input type="checkbox"/> |
| e) The worst pain imaginable | 0   | <input type="checkbox"/> |

##### 3) How often have you experienced discharge of fluid, pus or blood from your fistula?

- |                                    |     |                          |
|------------------------------------|-----|--------------------------|
| a) Never                           | 100 | <input type="checkbox"/> |
| b) Occasionally                    | 75  | <input type="checkbox"/> |
| c) A few times a week              | 50  | <input type="checkbox"/> |
| d) Daily                           | 25  | <input type="checkbox"/> |
| e) Several times a day/ constantly | 0   | <input type="checkbox"/> |

##### 4) How often have you been worried about not being able to control the passage of wind or leaking stool from your back passage or fistula?

- |                        |     |                          |
|------------------------|-----|--------------------------|
| a) Never               | 100 | <input type="checkbox"/> |
| b) Occasionally        | 75  | <input type="checkbox"/> |
| c) A few times a week  | 50  | <input type="checkbox"/> |
| d) Daily               | 25  | <input type="checkbox"/> |
| e) Several times a day | 0   | <input type="checkbox"/> |



# Audit timeline

Phase	Start Date	End Date	Duration
Centre Accrual	September 26 <sup>th</sup> , 2024	January 1 <sup>st</sup> , 2025	3 months
Patient Recruitment	<b>January 6<sup>th</sup>, 2025</b>	<b>March 31<sup>st</sup>, 2025</b>	3 months per centre
Patient Follow-up	Varies per patient	July 1 <sup>st</sup> , 2025	3 months per patient

# Cohort timeline


Phase	Start Date	End Date	Duration
Centre Accrual	September 26 <sup>th</sup> , 2024	March 31 <sup>st</sup> , 2025	6 months
Patient Recruitment	<b>April 1<sup>st</sup>, 2025</b>	<b>July 1<sup>st</sup>, 2025</b>	3 months per centre
Patient Follow-up	Varies per patient	July 1 <sup>st</sup> , 2026	12 months per patient

# Collaborative authorship

- Study Management Group
- National Coordinator



- Local Coordinator  
+ 4 collaborators




- MINIMUM of **10** patients per center
- 95% data-completeness




- Max: up to **5** per team

*Multiple teams per center possible*

# Audit overview



# Cohort overview



# Share the QR-code!

